CLINICAL CHEMISTRY HARR
問題一覧
1
D. Pregnancy or estrogens
2
D. TSH assay
3
A. Primary hyperthyroidism
4
C. Thyrotropin-releasing hormone (TRH) stimulation test
5
A. Formed in the blood by degradation of T4
6
A. Primary hyperthyroidism
7
C. Euthyroid with increased thyroxine-binding protein
8
B. TSH falls and thyroid hormones rise
9
D. After high-dose corticosteroid treatment
10
D. To determine whether the patient has been taking amphetamines
11
A. Relationship between drug dose and the drug blood level
12
B. Drug concentration at target sites and physiological effect
13
C. Testing for single nucleotide polymorphisms known to affect drug metabolism
14
C. Liberation, absorption, distribution, metabolism, excretion
15
D. Intravenous
16
C. Some drug is metabolized from the portal circulation, reducing bioavailability
17
A. Dose per hour = clearance (milligrams per hour) × average concentration at steady state ÷ f
18
B. Vd is the theoretical volume in liters into which the drug distributes
19
A. Clearance = elimination rate ÷ serum level
20
D. Oral dosing intervals give peaks and troughs in the dose-response curve
21
C. Dose interval should be increased
22
D. Be shortened, but dose per day not changed
23
A. Decrease the dose
24
D. Immediately before the next dose is given
25
A. Varies with the drug, depending on its rate of absorption
26
D. All of these options
27
A. One compartment, linear first-order elimination
28
C. Biphasic or two compartment with serum level rapidly falling in the first phase
29
A. Drug metabolites (e.g., N-acetylprocainamide) may need to be measured as well as parent drug
30
B. Peak blood sample
31
A
32
D. Aminoglycoside antibiotics
33
B. A drug is identified by comparing its Rf value and staining to standards
34
C. Enzyme conjugated to a drug
35
B. Formation of NADH is monitored at 340 nm
36
B. The enzyme donor and acceptor molecules are fragments of ß-galactosidase
37
C. When particle-bound drug binds to antibody, light scattering is increased
38
B. Selective ion monitoring
39
D. Creatinine 5 mg/dL
40
D. Marijuana
41
C. Bichromatic analysis is required in order to eliminate interference by oxyhemoglobin
42
A. Symptoms of intoxication usually begin when the level exceeds 0.05% w/v
43
A. Whole blood
44
C. Salicylate hydroxylase
45
D. Lead
46
D. Selenium
47
A. Navy blue top
48
B. 14 μg/dL
49
A. Blood copper and ceruloplasmin low, urinary copper excretion high
50
A. BRCA-1
51
A. Testing for recurrence
52
A. Creatine kinase-1 (CK-1)
53
C. CA-125
54
C. Nuclear matrix protein
55
C. Alkaline phosphatase isoenzymes
56
B. CA-15-3
57
B. It results from a translocation
58
D. Monitoring for recurrence of cancer
59
C. HER-2/ne
60
B. Plasma immunoassay for intact hCG and the β-hCG subunit
61
D. Transient hCG increase caused by chemotherapy
62
A. ER positive, PR positive
63
A. Hepatoma
64
C. Occult blood
65
D. p53 gene mutation
66
C. Neuroblastoma
67
D. Post–digital rectal examination
68
B. Free PSA below 25% is associated with malignant disease
69
A. Undetectable
other names parasitology
other names parasitology
Yves Laure Pimentel · 70問 · 2年前other names parasitology
other names parasitology
70問 • 2年前PARASITOLOGY
PARASITOLOGY
Yves Laure Pimentel · 111問 · 2年前PARASITOLOGY
PARASITOLOGY
111問 • 2年前HTMLBE
HTMLBE
Yves Laure Pimentel · 64問 · 2年前HTMLBE
HTMLBE
64問 • 2年前CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
Yves Laure Pimentel · 61問 · 2年前CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
61問 • 2年前HISTOPATHOLOGY
HISTOPATHOLOGY
Yves Laure Pimentel · 69問 · 2年前HISTOPATHOLOGY
HISTOPATHOLOGY
69問 • 2年前CC-2 SPECTROPHOTOMETRY
CC-2 SPECTROPHOTOMETRY
Yves Laure Pimentel · 100問 · 2年前CC-2 SPECTROPHOTOMETRY
CC-2 SPECTROPHOTOMETRY
100問 • 2年前CC-3 ELECTROPHORESIS
CC-3 ELECTROPHORESIS
Yves Laure Pimentel · 41問 · 2年前CC-3 ELECTROPHORESIS
CC-3 ELECTROPHORESIS
41問 • 2年前AUBF LAB SAFETY
AUBF LAB SAFETY
Yves Laure Pimentel · 87問 · 2年前AUBF LAB SAFETY
AUBF LAB SAFETY
87問 • 2年前CSF 1
CSF 1
Yves Laure Pimentel · 100問 · 2年前CSF 1
CSF 1
100問 • 2年前CSF 2
CSF 2
Yves Laure Pimentel · 82問 · 2年前CSF 2
CSF 2
82問 • 2年前SEMEN 1
SEMEN 1
Yves Laure Pimentel · 100問 · 2年前SEMEN 1
SEMEN 1
100問 • 2年前SEMEN 2
SEMEN 2
Yves Laure Pimentel · 7問 · 2年前SEMEN 2
SEMEN 2
7問 • 2年前SYNOVIAL FLUID 1
SYNOVIAL FLUID 1
Yves Laure Pimentel · 100問 · 2年前SYNOVIAL FLUID 1
SYNOVIAL FLUID 1
100問 • 2年前SYNOVIAL FLUID 2
SYNOVIAL FLUID 2
Yves Laure Pimentel · 6問 · 2年前SYNOVIAL FLUID 2
SYNOVIAL FLUID 2
6問 • 2年前SEROUS FLUID
SEROUS FLUID
Yves Laure Pimentel · 25問 · 2年前SEROUS FLUID
SEROUS FLUID
25問 • 2年前PLEURAL FLUID
PLEURAL FLUID
Yves Laure Pimentel · 44問 · 2年前PLEURAL FLUID
PLEURAL FLUID
44問 • 2年前PERICARDIAL FLUID
PERICARDIAL FLUID
Yves Laure Pimentel · 18問 · 2年前PERICARDIAL FLUID
PERICARDIAL FLUID
18問 • 2年前PERITONEAL FLUID/ ASCITIC FLUID
PERITONEAL FLUID/ ASCITIC FLUID
Yves Laure Pimentel · 30問 · 2年前PERITONEAL FLUID/ ASCITIC FLUID
PERITONEAL FLUID/ ASCITIC FLUID
30問 • 2年前AMNIOTIC FLUID
AMNIOTIC FLUID
Yves Laure Pimentel · 92問 · 2年前AMNIOTIC FLUID
AMNIOTIC FLUID
92問 • 2年前FECALYSIS
FECALYSIS
Yves Laure Pimentel · 80問 · 2年前FECALYSIS
FECALYSIS
80問 • 2年前OTHER BODY FLUIDS
OTHER BODY FLUIDS
Yves Laure Pimentel · 89問 · 2年前OTHER BODY FLUIDS
OTHER BODY FLUIDS
89問 • 2年前MTLBE- SUHO NOTES
MTLBE- SUHO NOTES
Yves Laure Pimentel · 86問 · 2年前MTLBE- SUHO NOTES
MTLBE- SUHO NOTES
86問 • 2年前MTLBE..
MTLBE..
Yves Laure Pimentel · 35問 · 2年前MTLBE..
MTLBE..
35問 • 2年前CC- CHROMATOGRAPHY
CC- CHROMATOGRAPHY
Yves Laure Pimentel · 19問 · 1年前CC- CHROMATOGRAPHY
CC- CHROMATOGRAPHY
19問 • 1年前CC-OSMOMETRY
CC-OSMOMETRY
Yves Laure Pimentel · 14問 · 1年前CC-OSMOMETRY
CC-OSMOMETRY
14問 • 1年前CC-ELECTROCHEMISTRY TECHNIQUES
CC-ELECTROCHEMISTRY TECHNIQUES
Yves Laure Pimentel · 43問 · 1年前CC-ELECTROCHEMISTRY TECHNIQUES
CC-ELECTROCHEMISTRY TECHNIQUES
43問 • 1年前CC- CARBOHYDRATES
CC- CARBOHYDRATES
Yves Laure Pimentel · 49問 · 2年前CC- CARBOHYDRATES
CC- CARBOHYDRATES
49問 • 2年前CC- DIABETES MELLITUS
CC- DIABETES MELLITUS
Yves Laure Pimentel · 97問 · 2年前CC- DIABETES MELLITUS
CC- DIABETES MELLITUS
97問 • 2年前MAJOR LIPOPROTEINS
MAJOR LIPOPROTEINS
Yves Laure Pimentel · 57問 · 2年前MAJOR LIPOPROTEINS
MAJOR LIPOPROTEINS
57問 • 2年前MINOR LIPOPROTEINS
MINOR LIPOPROTEINS
Yves Laure Pimentel · 63問 · 2年前MINOR LIPOPROTEINS
MINOR LIPOPROTEINS
63問 • 2年前PROTEINS
PROTEINS
Yves Laure Pimentel · 37問 · 2年前PROTEINS
PROTEINS
37問 • 2年前PLASMA PROTEINS 1
PLASMA PROTEINS 1
Yves Laure Pimentel · 91問 · 2年前PLASMA PROTEINS 1
PLASMA PROTEINS 1
91問 • 2年前PLASMA PROTEINS 2 (ALPHA 2 REGION)
PLASMA PROTEINS 2 (ALPHA 2 REGION)
Yves Laure Pimentel · 98問 · 2年前PLASMA PROTEINS 2 (ALPHA 2 REGION)
PLASMA PROTEINS 2 (ALPHA 2 REGION)
98問 • 2年前MISCELLANEOUS PROTEINS
MISCELLANEOUS PROTEINS
Yves Laure Pimentel · 61問 · 2年前MISCELLANEOUS PROTEINS
MISCELLANEOUS PROTEINS
61問 • 2年前Liver Function Test 1
Liver Function Test 1
Yves Laure Pimentel · 100問 · 2年前Liver Function Test 1
Liver Function Test 1
100問 • 2年前Liver Function Test 2
Liver Function Test 2
Yves Laure Pimentel · 96問 · 2年前Liver Function Test 2
Liver Function Test 2
96問 • 2年前TUMOR MARKERS
TUMOR MARKERS
Yves Laure Pimentel · 33問 · 2年前TUMOR MARKERS
TUMOR MARKERS
33問 • 2年前KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
Yves Laure Pimentel · 41問 · 2年前KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
41問 • 2年前GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES
Yves Laure Pimentel · 17問 · 2年前GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES
17問 • 2年前LIPID STORAGE DISEASES
LIPID STORAGE DISEASES
Yves Laure Pimentel · 14問 · 2年前LIPID STORAGE DISEASES
LIPID STORAGE DISEASES
14問 • 2年前PROTEINS
PROTEINS
Yves Laure Pimentel · 71問 · 2年前PROTEINS
PROTEINS
71問 • 2年前QUICK FIRE- ELECTRODES
QUICK FIRE- ELECTRODES
Yves Laure Pimentel · 7問 · 2年前QUICK FIRE- ELECTRODES
QUICK FIRE- ELECTRODES
7問 • 2年前ELECTROLYTES
ELECTROLYTES
Yves Laure Pimentel · 10問 · 2年前ELECTROLYTES
ELECTROLYTES
10問 • 2年前DRUGS
DRUGS
Yves Laure Pimentel · 27問 · 2年前DRUGS
DRUGS
27問 • 2年前TOXIC AGENTS:
TOXIC AGENTS:
Yves Laure Pimentel · 12問 · 2年前TOXIC AGENTS:
TOXIC AGENTS:
12問 • 2年前HEMATOLOGY 1 (HEMATOPOIESIS 1)
HEMATOLOGY 1 (HEMATOPOIESIS 1)
Yves Laure Pimentel · 100問 · 2年前HEMATOLOGY 1 (HEMATOPOIESIS 1)
HEMATOLOGY 1 (HEMATOPOIESIS 1)
100問 • 2年前HEMATOLOGY (HEMATOPOIESIS 2)
HEMATOLOGY (HEMATOPOIESIS 2)
Yves Laure Pimentel · 29問 · 2年前HEMATOLOGY (HEMATOPOIESIS 2)
HEMATOLOGY (HEMATOPOIESIS 2)
29問 • 2年前hema diseases
hema diseases
Yves Laure Pimentel · 25問 · 2年前hema diseases
hema diseases
25問 • 2年前AML
AML
Yves Laure Pimentel · 43問 · 2年前AML
AML
43問 • 2年前GLOBIN SYNTHESIS
GLOBIN SYNTHESIS
Yves Laure Pimentel · 71問 · 2年前GLOBIN SYNTHESIS
GLOBIN SYNTHESIS
71問 • 2年前HEMATOLOGY REFERENCE RANGES
HEMATOLOGY REFERENCE RANGES
Yves Laure Pimentel · 31問 · 2年前HEMATOLOGY REFERENCE RANGES
HEMATOLOGY REFERENCE RANGES
31問 • 2年前DISORDERS OF PRIMARY HEMOSTASIS
DISORDERS OF PRIMARY HEMOSTASIS
Yves Laure Pimentel · 34問 · 2年前DISORDERS OF PRIMARY HEMOSTASIS
DISORDERS OF PRIMARY HEMOSTASIS
34問 • 2年前PLATELET DISORDERS
PLATELET DISORDERS
Yves Laure Pimentel · 37問 · 2年前PLATELET DISORDERS
PLATELET DISORDERS
37問 • 2年前CHARACTERISTICS OF CLOTTING FACTORS
CHARACTERISTICS OF CLOTTING FACTORS
Yves Laure Pimentel · 100問 · 2年前CHARACTERISTICS OF CLOTTING FACTORS
CHARACTERISTICS OF CLOTTING FACTORS
100問 • 2年前4. CLASSIFICATION OF MACROPHAGE
4. CLASSIFICATION OF MACROPHAGE
Yves Laure Pimentel · 12問 · 2年前4. CLASSIFICATION OF MACROPHAGE
4. CLASSIFICATION OF MACROPHAGE
12問 • 2年前3. NATURAL OR INNATE IMMUNITY
3. NATURAL OR INNATE IMMUNITY
Yves Laure Pimentel · 39問 · 2年前3. NATURAL OR INNATE IMMUNITY
3. NATURAL OR INNATE IMMUNITY
39問 • 2年前5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
Yves Laure Pimentel · 55問 · 2年前5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
55問 • 2年前6. PHAGOCYTOSIS Chemotaxis
6. PHAGOCYTOSIS Chemotaxis
Yves Laure Pimentel · 37問 · 2年前6. PHAGOCYTOSIS Chemotaxis
6. PHAGOCYTOSIS Chemotaxis
37問 • 2年前8. NATURE OF ANTIGEN
8. NATURE OF ANTIGEN
Yves Laure Pimentel · 44問 · 2年前8. NATURE OF ANTIGEN
8. NATURE OF ANTIGEN
44問 • 2年前9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
Yves Laure Pimentel · 50問 · 2年前9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
50問 • 2年前1. HISTORY
1. HISTORY
Yves Laure Pimentel · 69問 · 2年前1. HISTORY
1. HISTORY
69問 • 2年前2. TYPES OF IMMUNITY
2. TYPES OF IMMUNITY
Yves Laure Pimentel · 38問 · 2年前2. TYPES OF IMMUNITY
2. TYPES OF IMMUNITY
38問 • 2年前7. PHAGOCYTOSIS Engulfment and Digestion
7. PHAGOCYTOSIS Engulfment and Digestion
Yves Laure Pimentel · 21問 · 2年前7. PHAGOCYTOSIS Engulfment and Digestion
7. PHAGOCYTOSIS Engulfment and Digestion
21問 • 2年前8. PHAGOCYTOSIS EXOCYTOSIS
8. PHAGOCYTOSIS EXOCYTOSIS
Yves Laure Pimentel · 15問 · 2年前8. PHAGOCYTOSIS EXOCYTOSIS
8. PHAGOCYTOSIS EXOCYTOSIS
15問 • 2年前10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
Yves Laure Pimentel · 32問 · 2年前10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
32問 • 2年前11. TRANSPLANTATION IMMUNOLOGY
11. TRANSPLANTATION IMMUNOLOGY
Yves Laure Pimentel · 30問 · 2年前11. TRANSPLANTATION IMMUNOLOGY
11. TRANSPLANTATION IMMUNOLOGY
30問 • 2年前2. LYMPHOID ORGANS
2. LYMPHOID ORGANS
Yves Laure Pimentel · 38問 · 2年前2. LYMPHOID ORGANS
2. LYMPHOID ORGANS
38問 • 2年前3. CLUSTER OF DIFFERENTIATION
3. CLUSTER OF DIFFERENTIATION
Yves Laure Pimentel · 48問 · 2年前3. CLUSTER OF DIFFERENTIATION
3. CLUSTER OF DIFFERENTIATION
48問 • 2年前4. T-CELL DIFFERENTIATION
4. T-CELL DIFFERENTIATION
Yves Laure Pimentel · 35問 · 2年前4. T-CELL DIFFERENTIATION
4. T-CELL DIFFERENTIATION
35問 • 2年前5. T CELL IMMUNODEFICIENCIES
5. T CELL IMMUNODEFICIENCIES
Yves Laure Pimentel · 18問 · 2年前5. T CELL IMMUNODEFICIENCIES
5. T CELL IMMUNODEFICIENCIES
18問 • 2年前6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
Yves Laure Pimentel · 44問 · 2年前6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
44問 • 2年前7. B CELL IMMUNODEFICIENCIES
7. B CELL IMMUNODEFICIENCIES
Yves Laure Pimentel · 23問 · 2年前7. B CELL IMMUNODEFICIENCIES
7. B CELL IMMUNODEFICIENCIES
23問 • 2年前8. COMBINED T CELL AND B CELL DEFICIENCIES
8. COMBINED T CELL AND B CELL DEFICIENCIES
Yves Laure Pimentel · 34問 · 2年前8. COMBINED T CELL AND B CELL DEFICIENCIES
8. COMBINED T CELL AND B CELL DEFICIENCIES
34問 • 2年前9. COMPARISON OF T AND B CELLS
9. COMPARISON OF T AND B CELLS
Yves Laure Pimentel · 12問 · 2年前9. COMPARISON OF T AND B CELLS
9. COMPARISON OF T AND B CELLS
12問 • 2年前10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
Yves Laure Pimentel · 16問 · 2年前10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
16問 • 2年前11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
Yves Laure Pimentel · 15問 · 2年前11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
15問 • 2年前12. ANTIBODY
12. ANTIBODY
Yves Laure Pimentel · 79問 · 2年前12. ANTIBODY
12. ANTIBODY
79問 • 2年前13. TYPES OF ANTIBODIES
13. TYPES OF ANTIBODIES
Yves Laure Pimentel · 97問 · 2年前13. TYPES OF ANTIBODIES
13. TYPES OF ANTIBODIES
97問 • 2年前14. MONOCLONAL ANTIBODIES
14. MONOCLONAL ANTIBODIES
Yves Laure Pimentel · 11問 · 2年前14. MONOCLONAL ANTIBODIES
14. MONOCLONAL ANTIBODIES
11問 • 2年前1. INTERLEUKINS
1. INTERLEUKINS
Yves Laure Pimentel · 23問 · 2年前1. INTERLEUKINS
1. INTERLEUKINS
23問 • 2年前2. INTERFERONS
2. INTERFERONS
Yves Laure Pimentel · 28問 · 2年前2. INTERFERONS
2. INTERFERONS
28問 • 2年前3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
Yves Laure Pimentel · 8問 · 2年前3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
8問 • 2年前4. COMPLEMENT SYSTEM
4. COMPLEMENT SYSTEM
Yves Laure Pimentel · 19問 · 2年前4. COMPLEMENT SYSTEM
4. COMPLEMENT SYSTEM
19問 • 2年前15. COMPLEMENT SYSTEM
15. COMPLEMENT SYSTEM
Yves Laure Pimentel · 76問 · 2年前15. COMPLEMENT SYSTEM
15. COMPLEMENT SYSTEM
76問 • 2年前16. SYSTEM CONTROLS/COMPLEMENT REGULATION
16. SYSTEM CONTROLS/COMPLEMENT REGULATION
Yves Laure Pimentel · 21問 · 2年前16. SYSTEM CONTROLS/COMPLEMENT REGULATION
16. SYSTEM CONTROLS/COMPLEMENT REGULATION
21問 • 2年前17. COMPLEMENT AND DISEASE STATES
17. COMPLEMENT AND DISEASE STATES
Yves Laure Pimentel · 29問 · 2年前17. COMPLEMENT AND DISEASE STATES
17. COMPLEMENT AND DISEASE STATES
29問 • 2年前18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
Yves Laure Pimentel · 19問 · 2年前18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
19問 • 2年前19. CYTOKINES
19. CYTOKINES
Yves Laure Pimentel · 22問 · 2年前19. CYTOKINES
19. CYTOKINES
22問 • 2年前20. INTERLEUKINS
20. INTERLEUKINS
Yves Laure Pimentel · 24問 · 2年前20. INTERLEUKINS
20. INTERLEUKINS
24問 • 2年前21. INTERFERONS, TNF, TGF, CHEMOKINE
21. INTERFERONS, TNF, TGF, CHEMOKINE
Yves Laure Pimentel · 21問 · 2年前21. INTERFERONS, TNF, TGF, CHEMOKINE
21. INTERFERONS, TNF, TGF, CHEMOKINE
21問 • 2年前1. SERO
1. SERO
Yves Laure Pimentel · 54問 · 2年前1. SERO
1. SERO
54問 • 2年前2. PRECIPITATION
2. PRECIPITATION
Yves Laure Pimentel · 38問 · 2年前2. PRECIPITATION
2. PRECIPITATION
38問 • 2年前3. PASSIVE IMMUNODIFFUSION
3. PASSIVE IMMUNODIFFUSION
Yves Laure Pimentel · 17問 · 2年前3. PASSIVE IMMUNODIFFUSION
3. PASSIVE IMMUNODIFFUSION
17問 • 2年前4. OUCHTERLONY
4. OUCHTERLONY
Yves Laure Pimentel · 15問 · 2年前4. OUCHTERLONY
4. OUCHTERLONY
15問 • 2年前5. ELECTROPHORETIC TECHNIQUE
5. ELECTROPHORETIC TECHNIQUE
Yves Laure Pimentel · 9問 · 2年前5. ELECTROPHORETIC TECHNIQUE
5. ELECTROPHORETIC TECHNIQUE
9問 • 2年前6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
Yves Laure Pimentel · 11問 · 2年前6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
11問 • 2年前7. IMMUNOFIXATION ELECTROPHORESIS
7. IMMUNOFIXATION ELECTROPHORESIS
Yves Laure Pimentel · 29問 · 2年前7. IMMUNOFIXATION ELECTROPHORESIS
7. IMMUNOFIXATION ELECTROPHORESIS
29問 • 2年前問題一覧
1
D. Pregnancy or estrogens
2
D. TSH assay
3
A. Primary hyperthyroidism
4
C. Thyrotropin-releasing hormone (TRH) stimulation test
5
A. Formed in the blood by degradation of T4
6
A. Primary hyperthyroidism
7
C. Euthyroid with increased thyroxine-binding protein
8
B. TSH falls and thyroid hormones rise
9
D. After high-dose corticosteroid treatment
10
D. To determine whether the patient has been taking amphetamines
11
A. Relationship between drug dose and the drug blood level
12
B. Drug concentration at target sites and physiological effect
13
C. Testing for single nucleotide polymorphisms known to affect drug metabolism
14
C. Liberation, absorption, distribution, metabolism, excretion
15
D. Intravenous
16
C. Some drug is metabolized from the portal circulation, reducing bioavailability
17
A. Dose per hour = clearance (milligrams per hour) × average concentration at steady state ÷ f
18
B. Vd is the theoretical volume in liters into which the drug distributes
19
A. Clearance = elimination rate ÷ serum level
20
D. Oral dosing intervals give peaks and troughs in the dose-response curve
21
C. Dose interval should be increased
22
D. Be shortened, but dose per day not changed
23
A. Decrease the dose
24
D. Immediately before the next dose is given
25
A. Varies with the drug, depending on its rate of absorption
26
D. All of these options
27
A. One compartment, linear first-order elimination
28
C. Biphasic or two compartment with serum level rapidly falling in the first phase
29
A. Drug metabolites (e.g., N-acetylprocainamide) may need to be measured as well as parent drug
30
B. Peak blood sample
31
A
32
D. Aminoglycoside antibiotics
33
B. A drug is identified by comparing its Rf value and staining to standards
34
C. Enzyme conjugated to a drug
35
B. Formation of NADH is monitored at 340 nm
36
B. The enzyme donor and acceptor molecules are fragments of ß-galactosidase
37
C. When particle-bound drug binds to antibody, light scattering is increased
38
B. Selective ion monitoring
39
D. Creatinine 5 mg/dL
40
D. Marijuana
41
C. Bichromatic analysis is required in order to eliminate interference by oxyhemoglobin
42
A. Symptoms of intoxication usually begin when the level exceeds 0.05% w/v
43
A. Whole blood
44
C. Salicylate hydroxylase
45
D. Lead
46
D. Selenium
47
A. Navy blue top
48
B. 14 μg/dL
49
A. Blood copper and ceruloplasmin low, urinary copper excretion high
50
A. BRCA-1
51
A. Testing for recurrence
52
A. Creatine kinase-1 (CK-1)
53
C. CA-125
54
C. Nuclear matrix protein
55
C. Alkaline phosphatase isoenzymes
56
B. CA-15-3
57
B. It results from a translocation
58
D. Monitoring for recurrence of cancer
59
C. HER-2/ne
60
B. Plasma immunoassay for intact hCG and the β-hCG subunit
61
D. Transient hCG increase caused by chemotherapy
62
A. ER positive, PR positive
63
A. Hepatoma
64
C. Occult blood
65
D. p53 gene mutation
66
C. Neuroblastoma
67
D. Post–digital rectal examination
68
B. Free PSA below 25% is associated with malignant disease
69
A. Undetectable